In vitro: alpha-synuclein, amyloid-beta [148,149]; in animal models of Parkinson’s disease [15,153]; phase 2 clinical trilas of squalamine phosphate for Parkinson’s disease [22,158]. Here, SNCA is linked to Parkinson disease.